Novo Nordisk Announces Shortage of 8 mg Vial Size of NovoSeven® RT
by Glenn Mones
Novo Nordisk has issued a supply notice informing patients and others that they will be unable to provide the 8 mg vial of NovoSeven® RT from January until mid-2024. Importantly, the overall supply of NovoSeven® RT is expected to remain intact as other vial sizes are available as a solution for those who would otherwise use the 8 mg vial. Patients can use the 1 mg, 2 mg, and 5 mg vials in combination to make the dose they need in absence of the 8 mg vial. Patients who have questions about how to make up their dose should consult their healthcare provider.
This is not a quality issue, according to the supply notice. . Novo Nordisk has decided to temporarily limit supply of the 8 mg vial because it requires the highest amount of Active Pharmaceutical Ingredient (API), which is currently constrained, compared to the other vial sizes. By re-directing the API towards the 1 mg, 2 mg, and 5 mg vial sizes, they can produce more and help ensure the overall supply of NovoSeven® RT remains intact for patients. Again, they don’t expect constraints on supply of the 1 mg, 2 mg, and 5 mg vials that would impact availability for patients.
A copy of the supply notice can be found HERE. If you have any questions, please reach out to your Novo Nordisk representative, or contact NovoCare customer support at 1-844-668-6732.
